Author

Esteban Tarazona-Guzman

Institution: University of California, San Francisco

Observed institution: University of California, San Francisco

OpenAlex ID: A5133946292

In Vivo Efficacy of ABHD17 Inhibition Validates the Palmitoylation Cycle as a Therapeutic Target in NRAS -Mutant Cancer

2025 · Matthew Decker, Benjamin J. Huang, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 3

In Vivo Efficacy of ABHD17 Inhibition Validates the Palmitoylation Cycle as a Therapeutic Target in NRAS-Mutant Cancer

2026 · Matthew Decker, Benjamin Huang, et al. · SSRN Electronic Journal

Works count: 2

Citation count: 3

H-index: 1

I10-index: